JP2005502616A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502616A5 JP2005502616A5 JP2003508379A JP2003508379A JP2005502616A5 JP 2005502616 A5 JP2005502616 A5 JP 2005502616A5 JP 2003508379 A JP2003508379 A JP 2003508379A JP 2003508379 A JP2003508379 A JP 2003508379A JP 2005502616 A5 JP2005502616 A5 JP 2005502616A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- neuropathy
- injury
- diseases
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 17
- 206010022114 Injury Diseases 0.000 claims 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 6
- 210000003169 Central Nervous System Anatomy 0.000 claims 5
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 5
- 210000001428 Peripheral Nervous System Anatomy 0.000 claims 5
- 201000001119 neuropathy Diseases 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000001988 toxicity Effects 0.000 claims 3
- 231100000419 toxicity Toxicity 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 2
- 230000004406 elevated intraocular pressure Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 1
- 206010061888 Amaurotic familial idiocy Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010001954 Amnestic disease Diseases 0.000 claims 1
- 208000003808 Amyloid Neuropathy Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 210000003050 Axons Anatomy 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 206010004659 Biliary cirrhosis Diseases 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 208000003295 Carpal Tunnel Syndrome Diseases 0.000 claims 1
- 201000011470 Charcot-Marie-Tooth disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 claims 1
- 206010012680 Diabetic neuropathy Diseases 0.000 claims 1
- 206010015037 Epilepsy Diseases 0.000 claims 1
- 201000005603 Fabry disease Diseases 0.000 claims 1
- 208000004929 Facial Paralysis Diseases 0.000 claims 1
- 206010017374 Friedreich's ataxia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019016 Haemorrhagic stroke Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000007999 Hyperesthesia Diseases 0.000 claims 1
- 206010020993 Hypoglycaemia Diseases 0.000 claims 1
- 206010021135 Hypovitaminosis Diseases 0.000 claims 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims 1
- 206010061256 Ischaemic stroke Diseases 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 206010025476 Malabsorption Diseases 0.000 claims 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims 1
- 229960000282 Metronidazole Drugs 0.000 claims 1
- 208000005264 Motor Neuron Disease Diseases 0.000 claims 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N Nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims 1
- 229960000564 Nitrofurantoin Drugs 0.000 claims 1
- 208000004361 Obstructive Lung Disease Diseases 0.000 claims 1
- 208000008760 Optic Nerve Disease Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 108009000578 Oxidative Stress Proteins 0.000 claims 1
- 102100004920 PEX7 Human genes 0.000 claims 1
- 108060006186 PHYH Proteins 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 208000008696 Polycythemia Vera Diseases 0.000 claims 1
- 206010036181 Porphyria Diseases 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 206010036673 Primary amyloidosis Diseases 0.000 claims 1
- 208000003055 Prion Disease Diseases 0.000 claims 1
- 206010061920 Psychotic disease Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 206010039911 Seizure Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010048676 Sjogren-Larsson syndrome Diseases 0.000 claims 1
- 208000005809 Status Epilepticus Diseases 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 206010046328 Uraemic neuropathy Diseases 0.000 claims 1
- 206010050040 VIIth nerve paralysis Diseases 0.000 claims 1
- 206010047627 Vitamin deficiency Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 230000001919 adrenal Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000001977 ataxic Effects 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 230000002218 hypoglycaemic Effects 0.000 claims 1
- 229960003350 isoniazid Drugs 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 230000000149 penetrating Effects 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 201000007737 retinal degeneration Diseases 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 201000011056 retinal disease Diseases 0.000 claims 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108020003112 toxins Proteins 0.000 claims 1
- 230000000304 vasodilatating Effects 0.000 claims 1
Claims (8)
- 中枢神経系(CNS)または末梢神経系(PNS)の神経変性を防止または阻止するための、CNSまたはPNSの神経再生を促進するための、グルタミン酸毒性からCNS細胞を保護するための、またはグルタミン酸毒性により引き起こされるかまたは悪化する損傷、障害または疾患を治療するための医薬組成物を調製するための、ポリ−Glu,Tyrの使用。
- 医薬組成物が、神経変性を防止または阻止するためにCNSまたはPNSの損傷、障害または疾患を治療するための、または神経再生を促進するための、またはグルタミン酸毒性により引き起こされるかまたは悪化するCNSまたはPNSの損傷、障害または疾患を治療するための医薬組成物である、請求項1の使用。
- 損傷、障害または疾患は、脊髄損傷、鈍的外傷、穿通性外傷、脳衝撃、対側衝撃、出血性発作、または虚血性発作である、請求項2の使用。
- 損傷は脊髄損傷である、請求項3の使用。
- 損傷、障害または疾患は、アルツハイマー病を含む老人性痴呆、パーキンソン病を含むパーキンソン症候群、顔面神経(ベル)まひ、ハンチントン舞踏病、筋萎縮性側策硬化症を含む運動ニューロン疾患、クロイツフェルト−ヤコブ病を含むプリオン病、アルパーズ病、バッテン病、コケーン症候群、レーヴィ小体疾患、発作重積状態、手根管症候群、椎間円板ヘルニア、ビタミン欠乏、てんかん、健忘症、不安症、痛覚過敏、精神病、発作、酸化ストレス、アヘン剤寛容と依存症、自己免疫疾患、またはアミロイド多発性神経炎のような疾患に関連する末梢血神経障害、糖尿病性ニューロパシー、尿毒症性ニューロパシー、ポルフィリン症性多発性ニューロパシー、低血糖症、シェーグレン・ラルソン症候群、急性感覚ニューロパシー、慢性失調性ニューロパシー、胆汁性肝硬変、原発性アミロイドーシス、閉塞性肺疾患、先端巨大症、吸収不良症候群、真性多血症、IgAおよびIgG免疫グロブリン血症、種々の薬剤(ニトロフラントイン、メトロニダゾール、イソニアジド、およびアルコールもしくは有機リン酸塩のような毒素)の合併症、シャルコー‐マリー‐ツース症候群、血管拡張性失調症、フリートライヒ運動失調、副腎脊髄神経障害、巨大軸索ニューロパシー、レフサム病、ファブリ病、またはリポタンパク質血漿である、請求項2の使用。
- 損傷、障害または疾患は、眼が関連し、視神経症、年齢関連黄斑変性、網膜変性などの網膜障害、または異常に上昇した眼圧に関連する疾患である、請求項2の使用。
- 異常に上昇した眼圧に関連する疾患は緑内障である、請求項6の使用。
- ポリ−Glu,Tyrがポリ−Glu50Tyr50である、請求項1から7のいずれかの使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/893,344 US6835711B2 (en) | 2001-06-28 | 2001-06-28 | Use of poly-Glu,Tyr for neuroprotective therapy |
PCT/IL2002/000517 WO2003002140A1 (en) | 2001-06-28 | 2002-06-27 | Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005502616A JP2005502616A (ja) | 2005-01-27 |
JP2005502616A5 true JP2005502616A5 (ja) | 2006-01-05 |
JP4434729B2 JP4434729B2 (ja) | 2010-03-17 |
Family
ID=25401407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003508379A Expired - Fee Related JP4434729B2 (ja) | 2001-06-28 | 2002-06-27 | 神経保護治療法のためのポリ−Glu,Tyrとこれで処理したT細胞の使用 |
Country Status (16)
Country | Link |
---|---|
US (1) | US6835711B2 (ja) |
EP (1) | EP1406650B1 (ja) |
JP (1) | JP4434729B2 (ja) |
KR (1) | KR20040032825A (ja) |
CN (1) | CN1326560C (ja) |
AT (1) | ATE412419T1 (ja) |
AU (1) | AU2002345323B2 (ja) |
CA (1) | CA2451521C (ja) |
DE (1) | DE60229639D1 (ja) |
DK (1) | DK1406650T3 (ja) |
ES (1) | ES2315371T3 (ja) |
HK (1) | HK1064951A1 (ja) |
IL (1) | IL159535A0 (ja) |
MX (1) | MXPA03011926A (ja) |
NZ (1) | NZ530261A (ja) |
WO (1) | WO2003002140A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7399740B2 (en) * | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
WO2004060266A2 (en) * | 2003-01-07 | 2004-07-22 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer poly-ye for therapeutic immunization |
SI1429800T1 (sl) * | 2001-12-06 | 2009-08-31 | Yeda Res & Dev | Cepivo in njegova uporaba za zdravljenje amiotrofiäśne lateralne skleroze |
US7960175B2 (en) | 2003-06-16 | 2011-06-14 | Kyushu University, National University Corporation | Process for producing human-origin immunocompetent cell |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
WO2005055920A2 (en) * | 2003-12-09 | 2005-06-23 | Yeda Research And Development Co. Ltd. | Compositions and methods for treatment of psychiatric disorders |
PT1701730E (pt) * | 2003-12-09 | 2013-11-27 | Yeda Res & Dev | Método e vacina compreendendo copolímero 1 para tratamento de distúrbios psiquiátricos |
EP1827108B1 (en) * | 2004-11-29 | 2015-04-08 | Yeda Research And Development Co., Ltd. | Induction of neurogenesis and stem cell therapy in combination with copolymer 1 |
US9220813B2 (en) * | 2005-04-18 | 2015-12-29 | Holy Cross Hospital, Inc. | Cell therapy for limiting overzealous inflammatory reactions in tissue healing |
US20100272787A1 (en) * | 2007-12-21 | 2010-10-28 | Ben Gurion University Of The Negev | Amethod of treating neurodegenerative diseases |
WO2009124170A1 (en) * | 2008-04-04 | 2009-10-08 | The Cleveland Clinic Foundation | Use of epineural sheath grafts for neural regeneration and protection |
SI2379087T1 (sl) * | 2008-12-19 | 2015-01-30 | DePuy Synthes Products, LLC | Celice, izpeljane iz popkovniäśnega tkiva, za zdravljenje nevropatske boleäśine in spastiäśnosti |
AU2010229651B2 (en) | 2009-03-26 | 2014-05-08 | Advanced Technologies And Regenerative Medicine, Llc | Human umbilical cord tissue cells as therapy for Alzheimer' s disease |
US20120171172A1 (en) * | 2009-09-04 | 2012-07-05 | Maria Siemionow | Methods Of Engineering Neural Tissue |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
HUE060304T2 (hu) | 2010-01-04 | 2023-02-28 | Mapi Pharma Ltd | Glatiramer acetátot tartalmazó depó rendszer |
EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1039929A1 (en) | 1998-07-21 | 2000-10-04 | YEDA RESEARCH AND DEVELOPMENT Co. Ltd. | Activated t-cells and their uses |
-
2001
- 2001-06-28 US US09/893,344 patent/US6835711B2/en not_active Expired - Fee Related
-
2002
- 2002-06-27 DE DE60229639T patent/DE60229639D1/de not_active Expired - Lifetime
- 2002-06-27 ES ES02743592T patent/ES2315371T3/es not_active Expired - Lifetime
- 2002-06-27 KR KR10-2003-7016949A patent/KR20040032825A/ko not_active Application Discontinuation
- 2002-06-27 MX MXPA03011926A patent/MXPA03011926A/es active IP Right Grant
- 2002-06-27 DK DK02743592T patent/DK1406650T3/da active
- 2002-06-27 CA CA2451521A patent/CA2451521C/en not_active Expired - Fee Related
- 2002-06-27 IL IL15953502A patent/IL159535A0/xx unknown
- 2002-06-27 AT AT02743592T patent/ATE412419T1/de not_active IP Right Cessation
- 2002-06-27 AU AU2002345323A patent/AU2002345323B2/en not_active Ceased
- 2002-06-27 CN CNB028165462A patent/CN1326560C/zh not_active Expired - Fee Related
- 2002-06-27 NZ NZ530261A patent/NZ530261A/en not_active IP Right Cessation
- 2002-06-27 EP EP02743592A patent/EP1406650B1/en not_active Expired - Lifetime
- 2002-06-27 WO PCT/IL2002/000517 patent/WO2003002140A1/en active Application Filing
- 2002-06-27 JP JP2003508379A patent/JP4434729B2/ja not_active Expired - Fee Related
-
2004
- 2004-10-12 HK HK04107851.9A patent/HK1064951A1/xx not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005502616A5 (ja) | ||
IL169552A (en) | An eye-drop-containing vaccine containing Copolymer 1 for systemic protection of the nervous system | |
CA2451521A1 (en) | Use of poly-glu, tyr for neuroprotective therapy | |
JP2006515870A5 (ja) | ||
Hohlfeld et al. | The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis | |
Mehanna et al. | Movement disorders in multiple sclerosis and other demyelinating diseases | |
Silver | Inhibitory molecules in development and regeneration | |
JP2019167381A5 (ja) | ||
JP2007500757A5 (ja) | ||
JP2004507460A5 (ja) | ||
BG106227A (en) | Thiazolo derivatives and pharmaceutical compositions containing them | |
AU4327101A (en) | Aminoadamantane derivatives as therapeutic agents | |
JP2008521796A5 (ja) | ||
WO2012006419A3 (en) | Pro-neurogenic compounds | |
MX2009012430A (es) | Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas. | |
WO2009038752A3 (en) | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses | |
JP2009530237A5 (ja) | ||
SG163526A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
JP2018509393A5 (ja) | ||
WO2007127393A3 (en) | Treatment and screening methods for promoting neurogenesis | |
WO2004089369A3 (en) | Methods and means for treating protein conformational disorders | |
JP2015514760A5 (ja) | ||
US7338976B1 (en) | Heterocyclic esters or amides for vision and memory disorders | |
WO2006072792A3 (en) | Compounds which bind to the active site of protein kinase enzymes |